Marrow transplantation therapy in mice with heritable blood disorders usually leads to rapid blood cell normalization, but is sometimes followed by pancytopenia and premature death. This is especially true in mice with Hertwig's anemia (an/an). Unlike the +I+ recipients, 100% of whom survive for over a year, 66% of the mutant mice die by 6 months posttransplantation, and the rest die soon thereafter. It is not clear whether premature death is due to the radiation dose (10 Gy) or to the fact that the F1 mutant mice receive parental-type cells known to induce hybrid resistance. In the present report, experiments were designed to determine whether the F1-an/an host is more sensitive to radiation and/or resistant to continued expansion of the parental-type +/+ cells. The mutant mice are, indeed, more sensitive to HE EFFICACY of marrow transplantation for severe heritable anemias was first shown in the mouse.' Therapy is not always successful and seems to be dependent on the disease under treatment. For example, mice with hereditary spherocytosis are completely repopulated by normal marrow after lethal' or sublethal irradiation: but remain anemic throughout life. Splenectomy by itself4 or subsequent to donor marrow repopulation' is not therapeutic. Furthermore, iron dextran injections after successful implantation do not alter the course of the disease.* Blood cell normalization does occur in mice with microcytic anemia, but only if iron supplementation is provided po~ttransplantation.~ Motheaten mice with a hereditary anemia accompanying an autoimmune-like disease show a postimplantation recurrence of the disease that ultimately causes death: Blood values in mice with Hertwig's anemia initially normalize: but severe pancytopenia ensues, and all recipients die before 7 months posttransplantation.' In most cases, the cause of treatment failure is unknown.
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Hertwig's anemia is a moderate to severe macrocytic, normocytic anemidpancytopenia; depending on the genetic background on which the mutant gene is fixed.' Hematopoietic stem cells are present, as adan marrow repopulates both lethally irradiated +/+ m i~e~.~ and stem cell-deficient W/ W mice4 and transfers the characteristic adan blood cell phenotype. Primordial germ cells are initially present at normal numbers, but most are lost during first meiosis and mitosis." Thus, two major cell populations are affected by the mutation, and their diminution appears to accompany expansion of the respective lineages.1o*" We predict that cell loss is initiated at metaphase when there are nonspecific additions (and deletions) of chromosomes in at least 10% of the mitotic cells.'* Hertwig's anemia bears some resemblance to Fanconi's anemia in humans,I3 as, in addition to the hematologic and cytogenetic problems, the mice almost invariably develop tumors as they age. However, thus far, an does not share a homologous chromosome location with the Fanconi-determining genes.I4
Given the cytogenetic anomalies in dividing cells of a d an mice and the resemblance to Fanconi's anemia, it was not surprising that the mutant mice died prematurely after 10 land-Stad) suggested that the X-irradiation sensitivity of the adan mice (695 rad), while different from their +/+ littermates (795 rad), was not nearly as severe as that in W/ W (240 to 280 rad)" or SI/Sp mice (125 to 175 rad)'6 maintained on the same genetic background. Therefore, we believed that, although increased radiation sensitivity might be a contributing factor to premature death, another candidate was the difference between donor and host tissue. In our previous experiments, the normal implant (to carry a genetic marker distinguishing it from the host) was from the C57BU6J (B6) strain, whereas the mutant recipient was an F1 hybrid between the B6 and the WB/Re (WB) &aim8
It is known that hybrid resistance, defined as growth resistance of a parental-type tissue in an F1 host, occurs during transfer of either WB or B6 cells into the WBB6Fl recipients." Resistance against the WB implant is stronger than that against the B6 implant.17 Donor WB and B6 spleen colony number is reduced below that detected in parent-toparent or F1-to-F1 transfers, thus indicating an early effect on either cell seeding or cell expansion. Normalization of the blood parameters in stem cell-deficient WBB6Fl-WW mutants occurs by 3 months posttransplantation in 100% of WBB6F1 +/+ cell recipients, but in only 71% of B6 +/+ cell recipients. This suggests that there is loss of donor B6 cells in some recipients. We suspected that F1 hybrid resistance might be augmented in the anemic adan recipients and could result in recurrence of the anemia through loss of maturing donor
There was, in fact, a continuous but more gradual decrease in red blood cell (RBC) counts in the lethally irradiated WBB6F1 +/+ control hosts injected The inset depicts survival of normal mice irradiated with 10 Gy (m) and mutant mice irradiated with 7 Gy (---l. For the first month, the mice were observed daily. The mutant survivors were examined at weekly intervals thereafter until 59 weeks. There were five mice in each group except the 6-Gy group, which had 13 mice.
with B6 + l + cells, which was consistent with hybrid resistance.* In the present study, mechanisms that might initiate premature death of the mice with Hertwig's anemia were investigated. The objective was to compare the y-irradiation sensitivity of the mutant and normal mice, to assess the effects of sublethal irradiation and normal marrow implantation on mutant life span, and to determine whether F1 hybrid resistance contributes to the recurring anemia in treated adan mice.
MATERIALS AND METHODS
Donor and recipient mice. All B6 +/+ donors were between the ages of 2 and 5 months and were homozygous for the hemoglobin marker Hbb' and the glucose phosphate isomerase marker Gpil". All primary WBB6FI-adan mice used as marrow recipients were 2 to 5 months old, heterozygous at the Hbb locus (Hbbd/Hbb' j, and homozygous for Gpil". The secondary recipients were stem celldeficient WBB6FI-WW mice 1 to 3.5 months of age. Male marrow was injected into males, whereas female marrow was injected into both male and female recipients with no graft-versus-host disease resulting. Mice irradiated without subsequent marrow transplantation were 2-to 4-month-old WBB6FI-+/+ and -adan females and males. In all cases, the Hertwig's anemia phenotype was confirmed by determining RBC parameters pretreatment. All mice tested, except the W/W" recipients, were irradiated with 6 to 10 Gy in a "7Cs irradiator at a dose rate of 2.2 Gylmin.
Donor marrow was flushed from the femurs into Dulbecco's phosphate-buffered saline ( I X PBS; GIBCO, Grand Island, NY). Cells were disaggregated by gentle aspiration through a 23-gauge needle, centrifuged, and resuspended in 1 mL 1 X PBS. Nucleated cells were counted in a hemacytometer and diluted to a concentration of 2 X IO' to 2.5 X 107/mL. Primary recipients received 2 X 10' cells, and secondary hosts received 2 X 10' to 2.5 X 10' cells injected via the tail vein.
Assessment qf blood parameters. One hematocrit tube of blood was obtained from the inner canthus at intervals of I month or longer. RBC number was determined on a model ZBI Coulter Counter (Coulter Immunology, Hialeah, FLj. Sealed hematocrit tubes were centrifuged in an Autocrit I1 (Clay Adams, Parsippany, NJ). The percentage of packed RBCs was measured and used to calculate the mean cell volume (MCV).
Cell separation. RBCs, granulocytes, lymphocytes, and platelets were separated using our modification" of the technique reported by Van Zant et al.*' Briefly, whole blood from one hematocrit tube was added to 10 mL 1 X PBS and centrifuged at 670g Platelets were isolated from the supernatant, and the pellet was eluted in 1 mL Percoll (1.07 g/mL density), underlaid with 2 mL Percoll (1.09 g/ mL), and overlaid with 1 mL IX PBS. Centrifugation at 1,000g for I O minutes left the lymphocytes at the PBS-Percoll interface, the granulocytes in the Percoll, and the RBCs in the pellet. 
RESULTS
Lifespan and blood phenotype of irradiated +/+ and mutant mice. To determine the radiation sensitivity of mice that are not marrow transplanted, both normal and mutant mice were exposed to increasing levels of y radiation. The LDloano is 7 Gy for the mutant mice and 10 Gy for +/+ mice (Fig 1) . The mean life span of adan mice irradiated with 6 Gy is approximately 50 weeks, as compared with 86.8 weeks for untreated mutant mice.' Thus, even sublethal irradiation decreases the life expectancy. There is a relationship between onset of severe anemia and death of the mutant mice as noted earlier.* RBC counts and hematocrits of sublethally irradiated (6 Gy) WBB6Fl-adan mice recover to preirradiation levels by 8 weeks (Fig 2A and B) . The RBC levels decline to 6 X 1061pL by 24 weeks postirradiation, and the number of survivors drops precipitously thereafter. It appears that the mutant mice are, indeed, much more radiation-sensitive than originally re~orted.~ Whether this reflects the difference in radiation source-y irradiation in the present report versus X-irradiation used previously-is unknown.
Lifespan and blood phenotype of irradiated mutant mice receiving normal marrow transplants. Previously, we established the effects of 10-Gy irradiation on blood parameters and life span of mutant and normal WBB6F1 hybrids injected with B6 +/+ cells.' Surprisingly, despite complete replacement of host with donor peripheral blood cells, all mutant mice were dead by 36 weeks, while all +/+ mice survived for over a year. Having now shown that 10 Gy is much above the LDlW for adun mice, it became important to determine whether +/+ implants could prolong life in mutant mice irradiated with lower doses. Consequently, treatment-induced changes were investigated in adan mice irradiated with a sublethal dose of 6 Gy or with lethal doses of 8 and 10 Gy. The donor cells, as in the original experiment, were from B6 +/+ mice and could induce F1 hybrid resistance. Figure 3 shows that deaths are radiation doserelated, and that the 6 Gy-irradiated mice survive at least twice as long as IO-Cy irradiated mice. Prolongation of the life span in sublethally irradiated mutant mice is suggestive but not conclusive evidence that radiation, not FI resistance, is the primary cause of premature death. RBC replacement is, as expected, more rapid and more complete in the mice irradiated with higher doses (Fig 4A) . Regardless of the radiation dose, the mutant mice recover from their genotype-determined anemia within the first 4 weeks, indicating that initially the treatment is therapeutic (Fig 4B) . RBC counts are maintained within the normal range for at least 32 weeks in mice irradiated with 6 Cy, but the counts decline gradually in these mice; counts decrease precipitously from 8 weeks in the mutant mice irradiated with 8 and I O Cy. Death occurs in the 8 Gy-irradiated mice after RBC counts decrease to or below 6 X IO"/pL. Marrow cells were collected separately from three moribund I O Gyirradiated mutants transplanted with B6 +/+ cells and were used in the subsequent experiment. Table l ) . Cure of the WMr macrocytic anemia coincides with repopulation, as evidenced by RBC counts, hematocrits, and MCVs. Of 12 mice injected (four each with cells from a single primary recipient), all survived for 52 weeks, and 1 1 lived for 102 weeks. Anemia does not recur in the secondary hosts. Interestingly, as noted previously for W W recipients injected with the equivalent of a single stem cell,'') the mice are chimeric for granulocytes, lymphocytes, and platelets for many months posttransplantation (Fig 5) . Thus, the irradiation-induced anemia in adan recipients after 8 weeks is caused by the hematopoietic environment. The stem cells from the original donor are, indeed, capable of normal function.
DISCUSSION
This report provides evidence that the adan mice are extremely sensitive to y irradiation and that it is the radiation damage rather than any complications caused by injection of parental cells into an FI hybrid that is responsible for premature death posttherapy. Supporting data include the facts that the life span, timing of anemia recurrence. and rate of donor RBC decrease are directly related to the radiation dose. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From host. Because, in these experiments, both the primary and the secondary recipient are F1 S, it is unlikely that hybrid resistance plays a major role in the recurrence of anemia and in the premature death of a d m mice.
The cause of the apparent marrow failure in the lethally irradiated adan recipients is an important topic for discussion. The marrow cellularity in morbid adan mice appears normal.' Supporting data from the present experiment are that approximately 1 X lo7 to 1.25 X lo7 marrow cells are collected from a single femur of the morbid adan recipients, while 1.5 X lo7 cells are collected from each femur of an untreated adan donor (data not shown). Nevertheless, the marrow in lethally irradiated adan recipient mice near death appears pale and particularly deficient in well-differentiated cells such as megakaryocytes, and the marrow alterations are accompanied by pancytopenia.' Nevertheless, even morbid adan primary hosts have the equivalent of at least one donor pluripotent hematopoietic stem cell per 2 X lo6 to 2.5 X lo6 marrow cells, based on previous titrations in a W W host." It is possible that signals to the marrow precursors are inefficient, the cells are destroyed in situ, or both mechanisms may lead to decreased numbers of peripheral blood cells.
A similar situation may occur in the sublethally irradiated mice with hemolytic anemia (sphh"/sphh"), where, despite complete repopulation with donor-derived RBCs, the mice remain
In both the adan and sphha/sphh" recipients of B6 +/+ cells, transfer of the marrow to W/w" mice results in repopulation with B6 cells, long-term survival of the secondary hosts, and cure of the W-induced anemia.3 Therefore, residence in an unfavorable environment does not have longterm effects on the original donor cells. Furthermore, splenic microvasculature-mediated destruction of the cells also appears unlikely, as removal of the spleen posttransplantation in the mice with hemolytic anemia further depresses rather than corrects the RJ3C count. One possibility is that autoantibodies generated during lysis of host cells before donor cell transfer increase. This seems unlikely in the adan mice, as there is complete replacement with B6 +/+ lymphocytes (data not shown) as well as RBCs; thus, autoantibodies would be generated by donor, not host, cells. Alternatively, as we suggested earlier, exhaustion or failure of some supportive cell type may occur in the primary recipients,' but the secondary recipient may have no microenvironmental deficiency. Further characterization of the murine defects leading to pancytopenia is of particular interest to the burgeoning field of marrow transfer in humans, as it may provide alternative explanations for apparent donor marrow failure in some recipients.
